Candel Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
CADL$9.49+8.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| DECEMBER 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $35,413 | $70,058 |
| Prepaid expenses and other current assets | $1,384 | 1,887 |
| Total current assets | 36,797 | 71,945 |
| Fixed assets, net | $3,206 | 4,424 |
| Lease right of use assets | $816 | 1,056 |
| Restricted cash | $266 | 266 |
| Other assets | $116 | — |
| Total assets | $41,201 | $77,691 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $422 | $380 |
| Accrued expenses | $4,356 | 4,723 |
| Current portion of term loan payable to a bank | $8,893 | — |
| Current portion of lease liability | $513 | 464 |
| Other current liabilities | $— | 48 |
| Total current liabilities | 14,184 | 5,615 |
| Deferred revenue | $— | 144 |
| Term loan payable to a bank | $11,632 | 20,202 |
| Other long-term debt | $751 | 648 |
| Lease liability, net of current portion | $973 | 1,486 |
| Warrant liability | $916 | 1,882 |
| Total liabilities | 28,456 | 29,977 |
| Commitments and contingencies (Note 15) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.01 par value; 10,000,000 shares authorized at December 31, 2023 and 2022; no shares issued or outstanding at December 31, 2023 and 2022, respectively. | $— | — |
| Common stock, $0.01 par value; 150,000,000 shares authorized at December 31, 2023 and 2022; 29,213,627 and 29,042,418 shares issued at December 31, 2023 and 2022, respectively; and 29,091,019 and 28,919,810 shares outstanding at December 31, 2023 and 2022, respectively. | $290 | 290 |
| Treasury stock (at cost) | $(448) | (448) |
| Additional paid-in capital | $149,931 | 146,961 |
| Accumulated deficit | $(137,028) | (99,089) |
| Total stockholders’ equity | 12,745 | 47,714 |
| Total liabilities and stockholders’ equity | $41,201 | $77,691 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.